

Clinical trials of glipizide GITS

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|---------------------------|
| glipizide GITS vs placebo (add on MET) | | | |
| Feinglos , 2005 n=61/61 follow-up: 16 weeks | 2.5 mg glipizide GITS versus placebo | type 2 diabetes inadequately controlled (A1c 7-8.5%) on metformin (>or =1000 mg/day for >or =3 months) | double-blind |

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - sulfonylureas for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q483>

References

Feinglos, 2005:

Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, Chaiken R, Kourides I Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005;68:167-75 [15860246] [10.1016/j.diabres.2004.09.002](https://doi.org/10.1016/j.diabres.2004.09.002)

Entry terms: glipizide, Glucotrol